Dulkadiroglu

Researchers are evaluating the effects of conventional free gingival graft (FGG) and modified free gingival graft (ModFGG) techniques on soft tissue thickness, volume changes, and creeping attachment in the lower front teeth (mandibular incisors). This randomized controlled clinical trial focuses on systemically healthy, non-smoking adults with localized Cairo Class II gingival recession. The study aims to provide clinical evidence on how the modified technique impacts soft tissue stability and volumetric gains compared to the conventional method, using advanced three-dimensional digital analysis. Participants will be randomly assigned to either the control group receiving the conventional FGG or the test group receiving the ModFGG. The ModFGG involves preparing a connective tissue flap from the area below the gum recession defect and rotating it to cover the exposed root before placing the free gingival graft harvested from the roof of the mouth. The conventional FGG places the graft directly without the connective tissue flap. Treatments are performed on the buccal surfaces of mandibular incisors with a vertical recession depth of 3 mm or more. Participants will undergo clinical and digital assessments before surgery and at 1, 3, and 6 months after surgery. These include soft tissue thickness and volumetric measurements by overlaying digital models obtained with an intraoral scanner. Additional clinical measures include gingival recession depth, keratinized tissue width, and probing pocket depth. The study will monitor soft tissue changes and overall treatment effects to determine the benefits of the modified graft technique over time.

This research aims to investigate the frequency of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) in children aged 2 to 6 who exhibit nonspecific neurological symptoms such as idiopathic seizures, speech disorders, and motor dysfunctions. The study targets children without hypoxic ischemic encephalopathy, head trauma, or developmental brain anomalies who visit Pediatric Metabolism, Neurology, and Developmental Pediatrics clinics over a 12-month enrollment period. It is a multicenter, non-drug screening study designed to better understand CLN2 disease among this population. During the study, demographic data, medical and family history will be collected at the first visit. Assessments will include seizure frequency, cognitive and language development evaluations, physical exams focusing on muscle strength, gait, and coordination, as well as neurological tests such as EEG and MRI scans. Children showing specific neurological signs or imaging findings will have blood samples taken for Tripeptidyl Peptidase 1 enzyme measurement. Those with low enzyme activity will undergo genetic testing to investigate CLN2 disease. Participants will be monitored for disease frequency over one year. Researchers will measure clinical and demographic characteristics including speech impairment, motor symptoms, EEG responses, and brain imaging changes. Safety monitoring includes obtaining informed consent and following up on enzyme and genetic test results. Total participation spans from initial screening through diagnostic testing and data collection during the 12-month study period.

Researchers are evaluating the effect of baxdrostat combined with dapagliflozin compared to baxdrostat with placebo on reducing albuminuria in people with chronic kidney disease (CKD) and high blood pressure. This Phase IIb, randomized, multicenter, double-blind study includes adults aged 18 years and older, with or without type 2 diabetes and regardless of current SGLT2 inhibitor treatment. The study aims to assess both the impact on albuminuria and the safety of these treatments. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or baxdrostat with a matching placebo. The study includes an optional pre-screening period to assess kidney function and other health markers, and those on SGLT2 inhibitors will undergo a washout before starting treatment. Randomization will consider diabetes status to ensure balanced groups. During the study, participants will be monitored up to 12 weeks to measure changes in albuminuria, specifically urinary albumin-to-creatinine ratio (UACR). Safety and other health parameters will also be assessed through blood tests and blood pressure measurements. The study ends when the last participant completes their final visit and procedures, ensuring thorough data collection on treatment effects and safety.

Researchers are investigating the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease (CKD) and high blood pressure. This Phase III, international, multicenter, double-blind, placebo-controlled study aims to see if this combination reduces risks such as significant kidney function decline, kidney failure, heart failure events, or cardiovascular death. The study includes a 4-week run-in period where participants not previously treated with SGLT2 inhibitors receive dapagliflozin alone. After this, participants are randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin in a double-blinded manner. Study visits occur frequently initially (at 2, 4, 8, 16, 34, and 52 weeks after randomization) and then approximately every 4 months. If participants stop the blinded treatment early, they continue dapagliflozin alone unless specific criteria require its discontinuation. Participants will undergo regular assessments including blood pressure monitoring and laboratory tests related to kidney function and cardiovascular health. The primary outcome measures the reduction in risk of major kidney and heart events over up to 37 months. Even if participants stop the study treatment, they will continue follow-up visits and data collection to ensure comprehensive safety and efficacy evaluation throughout the study duration.

Immunoglobulin A nephropathy (IgAN) is a kidney disease caused by the build-up of immune protein complexes in the kidneys, leading to inflammation and possible kidney damage. This Phase 3 study is evaluating how well mezagitamab, compared to a placebo, reduces protein levels in the urine (proteinuria) in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and its ability to maintain kidney function over the long term. Participants will be randomly assigned to one of two groups in the main study: two-thirds will receive mezagitamab injections under the skin, and one-third will receive placebo injections that look identical but have no active medicine. Treatment will occur in two 1-year cycles, each including about six months of dosing and six months of observation with monthly check-ups. An open-label group will include a small number of participants with lower proteinuria or kidney filtering issues, including those who previously received mezagitamab in another study; these participants will receive mezagitamab similarly to the main group. During the study, participants will visit the clinic several times for assessments. Researchers will monitor changes in proteinuria from the start through week 36, along with safety and kidney function. They will also perform regular evaluations and check-ups throughout each treatment and observation period to track participants' health and response to treatment.

Researchers are investigating adults aged 18 to 80 years who have sepsis caused by a suspected or confirmed bacterial infection and have developed acute kidney injury within 72 hours of sepsis onset. This Phase IIa, randomized, double-blind, placebo-controlled study aims to assess the safety, tolerability, and effectiveness of the drug AZD4144 compared to a placebo in improving kidney function in participants with sepsis-associated acute kidney injury (SA-AKI). Participants will be randomly assigned to receive either intravenous AZD4144 or a matching placebo once daily during the treatment period, which lasts the number of days specified in the study protocol. The study includes a screening period, the treatment period with daily drug administration, and a follow-up period that involves daily assessments while hospitalized and up to two outpatient visits after discharge. During the study, participants will undergo daily safety monitoring, blood and urine sample collection, and other assessments to track kidney function and overall health. The main outcome measured is the area under the curve (AUC) of 24-hour creatinine clearance during the treatment period. Researchers will continue to monitor participants for safety and recovery during hospitalization and follow-up visits, ensuring comprehensive evaluation of the treatments over the entire study duration.

This research investigates the long-term risk of stress caused by trauma in young people, specifically focusing on survivors of earthquakes. It aims to understand how trauma affects the autonomic nervous system and cardiovascular health, potentially leading to stress-related disorders. The study explores the use of a biofeedback method involving sound therapy to support stress management and coping in these individuals. Participants will receive different types of auditory stimulations during mental stress, including phonocardiography (PCG) auditory stimulation, MHR auditory stimulation, or no stimulation as a control. These sound therapies are designed to influence the vagal nerve and stabilize the autonomic nervous system by providing resonance-based biofeedback through heart sounds. During the study, various biological signals such as electrocardiography, phonocardiography, electrodermal activity, respiratory rhythm, and near-infrared spectroscopic imaging will be recorded. The emotional and psychological states of participants will be evaluated using these neuro-cardiac signals processed by deep learning models. The primary outcome will be measured after two months, with ongoing assessments of cardiovascular and neural activity effects related to trauma stress and biofeedback therapy.

Researchers are conducting a two-part, phase 2b/3 study to evaluate CSL300 (Clazakizumab) in adults with end stage kidney disease (ESKD) undergoing dialysis who have systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes. The study aims to determine the best dose of CSL300 and assess its effects on cardiovascular outcomes and safety in this population. This multicenter, randomized, double-blind, placebo-controlled trial targets patients with elevated inflammation markers and significant health risks due to their conditions. In the first part (phase 2b), the study focuses on finding the appropriate dose of CSL300 compared to placebo. CSL300 is given through intravenous (IV) administration. The second part (phase 3) evaluates the impact of CSL300 on cardiovascular events such as heart attack or cardiovascular death over approximately 5 years, continuing to compare CSL300 to placebo for safety and efficacy. The placebo matches CSL300's excipient content but lacks the active drug. Participants will undergo baseline and regular assessments for inflammation markers like high-sensitivity C-reactive protein (hs-CRP) up to 12 weeks in phase 2b, and long-term monitoring for cardiovascular outcomes in phase 3. The study involves ongoing safety evaluations and efficacy measurements during the entire follow-up period. This comprehensive approach helps researchers understand how CSL300 affects inflammation and cardiovascular health in patients with ESKD on dialysis.

Researchers are evaluating how different methods of education about human papillomavirus (HPV) affect knowledge and vaccination intention in young women aged 18 to 24 years living in the Af
5fin district of Kahramanmara
5f, Tfcrkiye. HPV is a leading cause of cervical cancer, and vaccination can prevent it. However, vaccination rates are low due to limited knowledge and misconceptions. This randomized controlled trial compares the impact of online video education, face-to-face education, and no education on HPV knowledge and vaccine intention. Participants will be randomly assigned to one of three groups: a video-based education group receiving a structured online video covering HPV infection, transmission, prevention, and vaccination; a face-to-face education group receiving the same information in person from a researcher; or a control group receiving no education. The study aims to see which method better improves knowledge and vaccination intention immediately after education and one month later. Participants will complete assessments at three times: before education (pre-test), immediately after education (post-test), and one month later (follow-up test). Data collection includes forms on participant information, HPV knowledge, and vaccination attitudes and intentions. The study measures how well education increases HPV knowledge and vaccine intention, comparing the effectiveness and lasting impact of the two education methods with the control group.

Medical advances in neonatal care have increased the survival of very low birth weight infants, leading to a rise in conditions like cerebral palsy, cardiorespiratory disorders, blindness, cognitive delays, and hearing impairments. Early diagnosis and intervention programs aim to support the motor, cognitive, and sensory development of these at-risk infants after discharge from the neonatal intensive care unit (NICU). This research investigates how early family-centered physiotherapy affects motor development, neurological examination, and cognitive and language skills in infants at 3 and 6 months of age compared to routine care. The study compares two groups: one receiving an early physiotherapy program involving family education on therapeutic holding, carrying, positioning, and sucking facilitation, integrated into daily routines with the whole family encouraged to participate; the other group receives a control intervention with a one-time session on positioning, holding, and carrying principles alongside routine NICU care at discharge. The physiotherapy program focuses on active motor learning and sensory strategy development in an enriched environment. Participants will be assessed using Prechtl's General Movements Assessment and Motor Optimality Score - Revised between 12 and 20 weeks postterm to measure motor quality and quantity. Researchers will monitor neurological, cognitive, and language development at 3 and 6 months. The study includes detailed evaluations to understand the impact of early physiotherapy on the neurodevelopment of at-risk infants, with monitoring occurring after NICU discharge and throughout the early months of life.